KBC Group’s Catalyst Pharmaceutical CPRX Stock Holding History

KBC Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154K	Hold	4,887	–	–	﹤0.01%	1157
2026 Q1	$121K	Buy	4,887 +1,500	+44%	+$35.7K	﹤0.01%	1211
2025 Q4	$79K	Hold	3,387	–	–	﹤0.01%	1431
2025 Q3	$67K	Hold	3,387	–	–	﹤0.01%	1510
2025 Q2	$73K	Sell	3,387 -1,312	-28%	-$31K	﹤0.01%	1406
2025 Q1	$114K	Hold	4,699	–	–	﹤0.01%	1407
2024 Q4	$98K	Buy	4,699 +1,542	+49%	+$33.1K	﹤0.01%	1564
2024 Q3	$63K	Hold	3,157	–	–	﹤0.01%	1593
2024 Q2	$49K	Hold	3,157	–	–	﹤0.01%	1631
2024 Q1	$50K	Hold	3,157	–	–	﹤0.01%	1557
2023 Q4	$53K	Sell	3,157 -518	-14%	-$7.08K	﹤0.01%	1481
2023 Q3	$43K	Sell	3,675 -3,929	-52%	-$52.6K	﹤0.01%	1561
2023 Q2	$102K	Sell	7,604 -625	-8%	-$8.99K	﹤0.01%	1173
2023 Q1	$136K	Hold	8,229	–	–	﹤0.01%	1098
2022 Q4	$153K	Hold	8,229	–	–	﹤0.01%	1055
2022 Q3	$106K	Buy	+8,229	New	+$97.5K	﹤0.01%	1160

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KBC Group's CPRX Position: Q2 2026 in Review

KBC Group held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 4,887 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

KBC Group first reported a position in CPRX in Q3 2022 and has held it in 16 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

KBC Group held 4,887 shares of Catalyst Pharmaceutical worth $154K as of Q2 2026.
KBC Group left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1157 holding.
KBC Group first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.